MRNA the wonderful thing is the news today was purely a bonus from from their old company Nastech. It will provide the revenues needed to take RNAi development to the next level without having to dilute or get any toxic financing.
Not to mention the $100's of millions MRNA could get from partnerships with Merck and other big pharma, much like RNAi did 2 years ago with Michael French who is now the ceo of MRNA.
Market Data 
Markets 
AI
